Tuoji Pharmaceuticals Secures $40 Million Series A Financing, Focusing on Bispecific Antibody-Drug Conjugates

Stock News11-12

Tuoji Pharmaceuticals has completed a $40 million Series A financing round, jointly led by Oriza Seed and Decheng Capital, with participation from Longpan Investment, Jifeng Capital, Mifen Health Fund, Songqing Capital, and Xiamen Jianfa.

According to public information, Tuoji Pharmaceuticals was established in early 2022. Its founder, Dr. Chen Zhaoyuan, is a senior scientist in the ADC field who has led the research and development of more than 10 ADC drug pipelines. The company focuses on bispecific antibody-drug conjugates (BsAb-ADC) and dual-payload ADCs, and has built a technology platform covering antibody discovery, Linker-Payload design, site-specific conjugation, and functional evaluation.

Its core product TJ101, a bispecific ADC targeting EGFR/B7-H3, is currently conducting clinical enrollment in both China and the United States.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment